Loading...
Serum level of IL-4 predicts response to topical immunotherapy with diphenylcyclopropenone in alopecia areata.
Gong, Y. Zhao, Y. Zhang, X. Qi, S. Li, S. Ye, Y. Yang, J. Caulloo, S. McElwee, Kevin J. Zhang, X.
Gong, Y.
Zhao, Y.
Zhang, X.
Qi, S.
Li, S.
Ye, Y.
Yang, J.
Caulloo, S.
McElwee, Kevin J.
Zhang, X.
Publication Date
2018
End of Embargo
Supervisor
Rights
© 2018 Wiley
This is the peer reviewed version of the following article: Gong Y, Zhao Y, Zhang X et al (2018) Serum level of IL-4 predicts response to topical immunotherapy with diphenylcyclopropenone in alopecia areata. Experimental Dermatology. 29:231-238, which has been published in final form at https://doi.org/10.1111/exd.13758. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving
Peer-Reviewed
Yes
Open Access status
openAccess
Accepted for publication
18/07/2018
Institution
Department
Awarded
Embargo end date
Collections
Additional title
Abstract
Background: This study investigated predictors of response to topical diphenylyclopropenone (DPCP) immunotherapy in patients with alopecia areata (AA).
Objective: To identify predictors of response, or resistance, to treatment for AA
through clinical observations and serum tests.
Methods: Eighty four AA patients were treated with DPCP. Serum cytokine levels
were measured in 33 AA patients pre- and post-treatment, and in 18 healthy controls, using ELISA assays.
Results: Of patients, 56.1% responded to DPCP with satisfactory hair regrowth; the
response rate was negatively correlated with hair loss extent. Before DPCP treatment, higher serum IFN-γ and IL-12 cytokine levels were observed in AA patients
compared to healthy controls. Non-responders to DPCP had significantly elevated
serum IL-4 pre-treatment (3.07 fold higher) and lower IL-12 levels compared with responders. After DPCP treatment, non-responders had persistently high IL-4, increased IL-12, negligible decrease in IFN-γ and decreased IL-10. Post-treatment DPCP
responders exhibited significantly decreased IFN-γ and IL-12, and increased IL-4 and
IL-10. Development of adverse side-effects was significantly associated with higher
pre-treatment serum IgE levels.
Limitations: A small number of subjects were evaluated.
Conclusions: Potentially, elevated pre-treatment serum levels of IL-4 and IL-12 can be
used as unfavorable and favorable predictors of DPCP therapeutic effect, respectively. In addition, pre-treatment elevated serum total IgE may predict increased risk
for severe adverse side-effects to DPCP application. Whether serum cytokine expression levels can be used as predictors of response to other forms of treatment is
unknown, but it may warrant investigation in the development of personalized treatments for AA.
Version
Accepted manuscript
Citation
Gong Y, Zhao Y, Zhang X et al (2018) Serum level of IL-4 predicts response to topical immunotherapy with diphenylcyclopropenone in alopecia areata. Experimental Dermatology. 29:231-238.
Link to publisher’s version
Link to published version
Link to Version of Record
Type
Article